Skip to main content
. 2018 May 16;11(5):450–460. doi: 10.1111/cts.12559

Figure 5.

Figure 5

Increasing application of RWD in drug development through (a) utilization of wearables in clinical trials and with payer assessments through (b) the use of value‐based pricing agreements. (a) Data extracted from https://clinicaltrials.gov using the search term “wearables.” (b) Data extracted from the University of Washington School of Pharmacy Performance Based Risk Sharing database.